BridgeBio Pharma Inc (BBIO)
Who owns BridgeBio Pharma Inc (BBIO)? This page shows the largest institutions and funds, the ownership structure and the latest insider transactions. 79.0% of the shares are freely tradable; institutional investors hold 103.2%.
Ownership Structure
Largest Shareholders
Institutions
| Name | Stake (%) | Shares | Change (%) | Date |
|---|---|---|---|---|
| BlackRock Inc | 7.25 | 14,207,757 | -2.3 | 03/31/2026 |
| Kohlberg Kravis Roberts & Co LP | 6.76 | 13,260,971 | +0.0 | 03/31/2026 |
| HHG PLC | 6.72 | 13,179,013 | +19.8 | 03/31/2026 |
| Viking Global Investors LP | 6.04 | 11,842,434 | -17.7 | 03/31/2026 |
| Farallon Capital Management, L.L.C. | 4.78 | 9,365,463 | +4.1 | 03/31/2026 |
| Vanguard Portfolio Management, LLC | 4.12 | 8,080,573 | +0.0 | 03/31/2026 |
| Vanguard Capital Management, LLC | 3.96 | 7,759,495 | +0.0 | 03/31/2026 |
| Aisling Capital Management LP | 2.60 | 5,089,611 | +0.0 | 03/31/2026 |
| State Street Corp | 2.52 | 4,934,320 | -0.6 | 03/31/2026 |
Funds
| Name | Stake (%) | Shares | Change (%) | Date |
|---|---|---|---|---|
| Vanguard Morn Total Stk Mkt Idx Investor | 2.86 | 5,601,518 | +0.8 | 06/30/2026 |
Largest reported positions according to regulatory filings; stake as a percentage of shares outstanding, change versus the previous filing. Source: fundamentals data.
Insider Transactions
| Date | Person | Role | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 9. Jul 2026 | Ellis Andrea | Director | Sell | 17,167 | 84.00 | 1,442,028 |
| 9. Jul 2026 | Ellis Andrea | Director | Other | 17,167 | 16.75 | 287,547 |
| 9. Jul 2026 | Cook Jennifer E. | Director | Sell | 112,422 | 90.00 | 10,117,980 |
| 9. Jul 2026 | Cook Jennifer E. | Director | Sell | 36,167 | 84.00 | 3,038,028 |
| 9. Jul 2026 | Cook Jennifer E. | Director | Other | 17,167 | 16.75 | 287,547 |
| 9. Jul 2026 | Cook Jennifer E. | Director | Other | 112,422 | 29.00 | 3,260,238 |
| 9. Jul 2026 | Cook Jennifer E. | Director | Other | 19,000 | 8.45 | 160,550 |
Reportable transactions by officers and major shareholders from SEC Form 4 filings. "Other" includes things like stock grants and option exercises without a buy/sell character.
View all insider transactions →Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.